Cite
VP.56a Real-world assessment of onasemnogene abeparvovec treatment in patients with spinal muscular atrophy: RESTORE/post-marketing surveillance in Japan.
MLA
Saito, K., et al. “VP.56a Real-World Assessment of Onasemnogene Abeparvovec Treatment in Patients with Spinal Muscular Atrophy: RESTORE/Post-Marketing Surveillance in Japan.” Neuromuscular Disorders, vol. 32, Oct. 2022, pp. S92–93. EBSCOhost, https://doi.org/10.1016/j.nmd.2022.07.191.
APA
Saito, K., Nagao, R., Tsuchida, K., Teshima, R., & Kawase, K. (2022). VP.56a Real-world assessment of onasemnogene abeparvovec treatment in patients with spinal muscular atrophy: RESTORE/post-marketing surveillance in Japan. Neuromuscular Disorders, 32, S92–S93. https://doi.org/10.1016/j.nmd.2022.07.191
Chicago
Saito, K., R. Nagao, K. Tsuchida, R. Teshima, and K. Kawase. 2022. “VP.56a Real-World Assessment of Onasemnogene Abeparvovec Treatment in Patients with Spinal Muscular Atrophy: RESTORE/Post-Marketing Surveillance in Japan.” Neuromuscular Disorders 32 (October): S92–93. doi:10.1016/j.nmd.2022.07.191.